RT Book, Section
A1 Shen, Jia
A1 Henry, Timothy D.
A1 Quyyumi, Arshed A.
A2 Samady, Habib
A2 Fearon, William F.
A2 Yeung, Alan C.
A2 King III, Spencer B.
SR Print(0)
ID 1146607053
T1 Cell Therapy for Cardiovascular Diseases
T2 Interventional Cardiology, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071820363
LK accesscardiology.mhmedical.com/content.aspx?aid=1146607053
RD 2024/04/19
AB Ischemic  heart  disease  and  heart  failure  continue  to  be  the  predominant  causes  of  morbidity  and  mortality  worldwide.  Acute  myocardial  infarction  is  the  most  common  cause  of  heart  failure  and  triggers  a  series  of  cellular  and  molecular  changes  leading  to  apoptosis,  necrosis,  hypertrophy  of  cardiomyocytes,  impaired  neovascularization,  interstitial  fibrosis,  inflammation,  reduced  contractility,  and  pathologic  remodeling.1  Despite  advances  in  medical  and  device  therapy,  hospitalization  rates  and  mortality  for  heart  failure  continue  to  remain  high,  with  1  in  5  patients  dying  within  12  months  of  diagnosis.2  Medical  therapy  has  centered  on  the  treatment  of  underlying  risk  factors  and  on  the  initiation  of  antiplatelet,  lipid-lowering,  β-adrenergic  receptor,  and  angiotensin  antagonist  therapy.  Interventions  designed  to  facilitate  cardiovascular  regeneration  were  not  initially  pursued  because  it  was  assumed  that  the  adult  heart  is  a  terminally  differentiated  postmitotic  organ  where  the  number  of  cardiomyocytes  are  established  at  birth,  with  no  potential  for  regeneration  after  damage.3